CN108473562B - 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 - Google Patents

抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 Download PDF

Info

Publication number
CN108473562B
CN108473562B CN201680072782.7A CN201680072782A CN108473562B CN 108473562 B CN108473562 B CN 108473562B CN 201680072782 A CN201680072782 A CN 201680072782A CN 108473562 B CN108473562 B CN 108473562B
Authority
CN
China
Prior art keywords
seq
hvr
amino acid
acid sequence
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680072782.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN108473562A (zh
Inventor
仓持太一
井川智之
坚田仁
堀裕次
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority to CN202210678733.5A priority Critical patent/CN115028721A/zh
Publication of CN108473562A publication Critical patent/CN108473562A/zh
Application granted granted Critical
Publication of CN108473562B publication Critical patent/CN108473562B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680072782.7A 2015-12-18 2016-12-16 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法 Active CN108473562B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210678733.5A CN115028721A (zh) 2015-12-18 2016-12-16 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015247070 2015-12-18
JP2015-247070 2015-12-18
PCT/JP2016/087487 WO2017104783A1 (en) 2015-12-18 2016-12-16 Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210678733.5A Division CN115028721A (zh) 2015-12-18 2016-12-16 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法

Publications (2)

Publication Number Publication Date
CN108473562A CN108473562A (zh) 2018-08-31
CN108473562B true CN108473562B (zh) 2022-06-17

Family

ID=59011957

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210678733.5A Pending CN115028721A (zh) 2015-12-18 2016-12-16 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
CN201680072782.7A Active CN108473562B (zh) 2015-12-18 2016-12-16 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210678733.5A Pending CN115028721A (zh) 2015-12-18 2016-12-16 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法

Country Status (16)

Country Link
EP (1) EP3390443A4 (ko)
JP (4) JP6142069B1 (ko)
KR (4) KR20240058997A (ko)
CN (2) CN115028721A (ko)
AR (1) AR107078A1 (ko)
AU (1) AU2016372934B2 (ko)
BR (1) BR112018011073A2 (ko)
CA (1) CA3002422C (ko)
EA (1) EA201891420A1 (ko)
HK (1) HK1254755A1 (ko)
MX (1) MX2018007145A (ko)
MY (1) MY189425A (ko)
PH (1) PH12018501280A1 (ko)
SG (2) SG11201610812WA (ko)
TW (3) TW202231662A (ko)
WO (1) WO2017104783A1 (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
CN107488228A (zh) 2008-04-11 2017-12-19 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
RU2658504C9 (ru) 2010-11-30 2018-08-21 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
CN107964042B (zh) 2012-05-30 2022-04-19 中外制药株式会社 靶组织特异性抗原结合分子
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
KR20210084688A (ko) 2012-08-24 2021-07-07 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
EP3783017A1 (en) 2013-04-02 2021-02-24 Chugai Seiyaku Kabushiki Kaisha Fc region variant
AU2014358191B2 (en) 2013-12-04 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
EP3240804A4 (en) 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
TW202231662A (zh) * 2015-12-18 2022-08-16 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
EA201990017A1 (ru) * 2016-06-17 2019-07-31 Чугаи Сейяку Кабусики Кайся Антитела к миостатину и способы их применения
KR20230079499A (ko) 2016-08-05 2023-06-07 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
WO2018160683A1 (en) 2017-02-28 2018-09-07 Seattle Genetics, Inc. Cysteine mutated antibodies for conjugation
KR102259473B1 (ko) 2018-08-10 2021-06-02 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
KR20210149779A (ko) * 2019-04-10 2021-12-09 추가이 세이야쿠 가부시키가이샤 Fc 영역 개변 항체의 정제 방법
EP4028417A4 (en) * 2019-09-13 2024-01-24 Admare Therapeutics Soc ANTIBODIES AGAINST ONCOLYTIC VIRUS ANTIGEN AND METHODS OF USE THEREOF
RU2750267C1 (ru) * 2020-02-07 2021-06-25 Общество с ограниченной ответственностью «НАУЧНО-ПРОИЗВОДСТВЕННОЕ ОБЪЕДИНЕНИЕ ИН-ВЕТ» Рекомбинантный ростовой дифференцировочный фактор роста 11 (GDF11), способ его получения, инъекционный препарат для повышения мышечной массы млекопитающих животных и птицы, а также способ использования препарата
TW202144395A (zh) 2020-02-12 2021-12-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
CN118055767A (zh) 2021-10-06 2024-05-17 豪夫迈·罗氏有限公司 新颖的组合施用
WO2023187022A1 (en) 2022-04-01 2023-10-05 F. Hoffmann-La Roche Ag New treatment for facioscapulohumeral muscular dystrophy (fshd)
TWI833641B (zh) 2022-05-02 2024-02-21 丹麥商諾佛 儂迪克股份有限公司 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體
WO2024081932A1 (en) 2022-10-14 2024-04-18 Genentech, Inc. Methods for treating spinal muscular atrophy
CN116990528B (zh) * 2023-09-27 2024-02-06 成都华西海圻医药科技有限公司 一种基于Gyrolab平台快速测定抗CD40单抗的分析方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101230102A (zh) * 2002-10-22 2008-07-30 惠氏公司 抗gdf-8的中和抗体及其用途
CN101511871A (zh) * 2006-09-05 2009-08-19 伊莱利利公司 抗肌肉生长抑制因子抗体
WO2010070094A1 (en) * 2008-12-19 2010-06-24 Glaxo Group Limited Myostatin binding proteins
WO2011151432A1 (en) * 2010-06-03 2011-12-08 Glaxo Group Limited Humanised antigen binding proteins to myostatin6
CN102993304A (zh) * 2008-04-11 2013-03-27 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
SI1797127T1 (sl) * 2004-09-24 2017-09-29 Amgen Inc. Modificirane fc-molekule
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PE20091163A1 (es) * 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
SG10201507722QA (en) * 2010-03-11 2015-10-29 Rinat Neuroscience Corp ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
EP3348140B1 (en) * 2012-03-16 2020-12-30 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗－ｈｌａ－ｂ*２７抗體及其用途
EA028244B1 (ru) * 2012-08-13 2017-10-31 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА К PCSK9 C pH-ЗАВИСИМЫМИ ХАРАКТЕРИСТИКАМИ СВЯЗЫВАНИЯ
KR20210084688A (ko) * 2012-08-24 2021-07-07 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
CA2911514A1 (en) * 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CA2918300A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Methods of treating sporadic inclusion body myositis
JP6706617B2 (ja) * 2014-11-06 2020-06-10 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． 抗プロ／潜在型−ミオスタチン抗体およびその使用
WO2016073879A2 (en) * 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EP3240804A4 (en) * 2014-12-19 2019-01-09 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES, POLYPEPTIDES WITH DEVIANT FC REGIONS AND METHOD OF USE
TW202231662A (zh) 2015-12-18 2022-08-16 日商中外製藥股份有限公司 抗肌抑素抗體、含變異fc區之多肽及使用方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101230102A (zh) * 2002-10-22 2008-07-30 惠氏公司 抗gdf-8的中和抗体及其用途
CN101511871A (zh) * 2006-09-05 2009-08-19 伊莱利利公司 抗肌肉生长抑制因子抗体
CN102993304A (zh) * 2008-04-11 2013-03-27 中外制药株式会社 与多个分子的抗原反复结合的抗原结合分子
WO2010070094A1 (en) * 2008-12-19 2010-06-24 Glaxo Group Limited Myostatin binding proteins
WO2011151432A1 (en) * 2010-06-03 2011-12-08 Glaxo Group Limited Humanised antigen binding proteins to myostatin6

Also Published As

Publication number Publication date
JP6142069B1 (ja) 2017-06-07
CN115028721A (zh) 2022-09-09
SG11201610812WA (en) 2017-07-28
MX2018007145A (es) 2018-08-15
AU2016372934B2 (en) 2023-10-05
MY189425A (en) 2022-02-10
TW201808992A (zh) 2018-03-16
KR20170085028A (ko) 2017-07-21
KR20180085711A (ko) 2018-07-27
HK1254755A1 (zh) 2019-07-26
KR102501335B1 (ko) 2023-02-17
JP2017148069A (ja) 2017-08-31
TWI749057B (zh) 2021-12-11
RU2018125431A (ru) 2020-01-20
KR20240058997A (ko) 2024-05-03
RU2018125431A3 (ko) 2020-07-06
JP2022097485A (ja) 2022-06-30
TWI605057B (zh) 2017-11-11
BR112018011073A2 (pt) 2018-11-21
AU2016372934A1 (en) 2018-05-10
EP3390443A4 (en) 2019-11-13
KR20230027321A (ko) 2023-02-27
CA3002422A1 (en) 2017-06-22
TW202231662A (zh) 2022-08-16
CA3002422C (en) 2024-04-16
SG10201707267RA (en) 2017-10-30
JP7053164B2 (ja) 2022-04-12
PH12018501280A1 (en) 2019-01-28
TW201726718A (zh) 2017-08-01
KR101820637B1 (ko) 2018-01-19
JP2017112997A (ja) 2017-06-29
WO2017104783A1 (en) 2017-06-22
CN108473562A (zh) 2018-08-31
EP3390443A1 (en) 2018-10-24
AR107078A1 (es) 2018-03-21
EA201891420A1 (ru) 2019-02-28
JP2024023427A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
CN108473562B (zh) 抗-肌肉生长抑制因子抗体、包含变体fc区的多肽及使用方法
CN109311969B (zh) 抗-肌肉生长抑制因子抗体及使用方法
US10738111B2 (en) Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use
RU2778945C2 (ru) Антитела к миостатину и способы их применения
RU2789884C2 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
RU2799522C2 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA044612B1 (ru) Антитела к миостатину и способы их применения
EA041641B1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA040713B1 (ru) Антитело к миостатину и способы его получения, выделенная нуклеиновая кислота, кодирующая антитело, клетка-хозяин и фармацевтическая композиция для увеличения клиренса миостатина

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254755

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant